Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INMB 
INmune Bio Inc (INMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/04/2025: INMB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -14.76% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 185.05M USD | Price to earnings Ratio - | 1Y Target Price 23.4 |
Price to earnings Ratio - | 1Y Target Price 23.4 | ||
Volume (30-day avg) 444620 | Beta 1.94 | 52 Weeks Range 4.32 - 12.72 | Updated Date 04/2/2025 |
52 Weeks Range 4.32 - 12.72 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.11 |
Earnings Date
Report Date 2025-03-26 | When After Market | Estimate -0.54 | Actual -0.4 |
Profitability
Profit Margin - | Operating Margin (TTM) -304535.72% |
Management Effectiveness
Return on Assets (TTM) -55.19% | Return on Equity (TTM) -119.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 153503060 | Price to Sales(TTM) 13217.68 |
Enterprise Value 153503060 | Price to Sales(TTM) 13217.68 | ||
Enterprise Value to Revenue 10964.5 | Enterprise Value to EBITDA -5.31 | Shares Outstanding 22930300 | Shares Floating 14932219 |
Shares Outstanding 22930300 | Shares Floating 14932219 | ||
Percent Insiders 27.78 | Percent Institutions 27.69 |
Analyst Ratings
Rating 4.5 | Target Price 19.83 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
INmune Bio Inc
Company Overview
History and Background
INmune Bio Inc. is a clinical-stage immunotherapy company focused on developing therapies that harness the power of the innate immune system to fight disease. Founded in 2005, the company's primary focus is on developing therapies for Alzheimer's disease and other diseases of the innate immune system. They have several clinical programs in progress and aim to address significant unmet medical needs.
Core Business Areas
- Neuroinflammation: Developing XPro1595, a dominant-negative tumor necrosis factor (TNF) inhibitor, for the treatment of Alzheimer's disease by targeting neuroinflammation.
- Cancer Immunotherapy: Developing INKmune, a Natural Killer (NK) cell therapeutic that primes NK cells to attack tumor cells by removing inhibitory signals from the tumor microenvironment. Also, DN-TNF programs in immuno-oncology.
Leadership and Structure
Dr. Raymond J. Tesi is the CEO and President. The company has a board of directors and a management team focused on clinical development and regulatory approval of their therapeutic candidates. The organization has research, clinical development, and administrative departments.
Top Products and Market Share
Key Offerings
- XPro1595: XPro1595 is a dominant-negative TNF inhibitor in clinical development for Alzheimer's disease. There are no approved therapies to target this pathway in Alzheimer's, making market share potential dependent on efficacy and regulatory approval. Competitors include companies developing other Alzheimer's therapies, such as Eisai/Biogen with Leqembi.
- INKmune: INKmune is a Natural Killer (NK) cell therapeutic being developed for cancer immunotherapy. The market share potential depends on clinical trial success and regulatory approval. Competitors include companies developing CAR-NK and other NK cell therapies such as Fate Therapeutics.
Market Dynamics
Industry Overview
The immunotherapy and Alzheimer's disease markets are experiencing rapid growth due to advancements in understanding disease mechanisms and the development of novel therapeutic approaches. The cancer immunotherapy market is driven by the increasing prevalence of cancer and the success of checkpoint inhibitors and cell therapies.
Positioning
INmune Bio is positioned as an innovator in the innate immune system space, with a focus on targeting TNF and leveraging NK cells for therapeutic benefit. Their competitive advantage lies in their unique approach to modulating the immune system to treat neurodegenerative diseases and cancer.
Total Addressable Market (TAM)
The TAM for Alzheimer's disease therapies is estimated to be billions of dollars annually, with similar potential in cancer immunotherapy. INmune Bio's positioning in targeting neuroinflammation and NK cell activation places them to capitalize on a portion of this TAM, dependent on clinical success and market adoption.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Experienced leadership team
- Strong intellectual property position
- Targeting unmet medical needs
Weaknesses
- Clinical stage company with no approved products
- Limited financial resources
- High risk of clinical trial failure
- Reliance on successful fundraising
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- FDA breakthrough therapy designation
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure to secure funding
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- EISI (ESAI)
- BIIB (Biogen)
- FATE
Competitive Landscape
INmune Bio's competitive advantages lie in their unique therapeutic approaches targeting neuroinflammation and NK cell activation. However, they face significant competition from larger, more established pharmaceutical companies with greater resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing clinical programs, securing funding, and establishing partnerships.
Future Projections: Future growth depends on clinical trial success and regulatory approval. Analyst estimates vary widely based on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing XPro1595 in Alzheimer's disease trials and INKmune in cancer immunotherapy trials.
Summary
INmune Bio Inc. is a clinical-stage company pioneering novel immunotherapies for Alzheimer's and cancer. The company's strengths lie in its innovative approaches and experienced leadership, but it faces the inherent risks of clinical development and funding challenges. Positive clinical trial results could unlock significant growth opportunities, while regulatory hurdles and competition pose ongoing threats. Securing partnerships and demonstrating clinical efficacy will be critical for INmune Bio's long-term success.
Similar Companies
AGEN
Agenus Inc
AGEN
Agenus Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
FATE
Fate Therapeutics Inc
FATE
Fate Therapeutics Inc
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment in INmune Bio Inc. involves significant risks, including the risk of loss of investment. Market share estimations are approximated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INmune Bio Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2019-02-04 | Co-Founder, President, CEO, Chief Medical Officer & Chairman Dr. Raymond Joseph Tesi M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.inmunebio.com |
Full time employees 13 | Website https://www.inmunebio.com | ||
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.